Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

AstraZeneca AZ research Lund Sweden 

AstraZeneca (AZ) has started late-stage clinical trials of its MEK inhibitor selumetinib in advanced non-small-cell lung cancer (NSCLC).

The drug is being investigated with docetaxel as a second-line treatment for NSCLC tumours that are KRAS mutation positive, a sub-type of lung cancer associated with poor prognosis and limited treatment options.

The SELECT-1 trial is the largest prospective study ever conducted in this patient population and AZ hopes to show the combination is better than chemotherapy alone.

It will enrol more than 630 patients who will receive either a twice-daily 75mg dose of selumetinib or placebo in combination with docetaxel, administered intravenously on a 21-day cycle.

Antoine Yver, head of oncology in AZ's Global Medicines Development unit, said: “To our knowledge, SELECT-1 will be the first phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone in KRAS mutation positive advanced or metastatic non-small cell lung cancer.

“This is an area of pressing clinical need, and our decision to progress selumetinib was based on phase II results, which showed promising clinical activity in this group of patients.”


Selumetinib was moved into phase III trials after positive phase II results showing selumetinib plus docetaxel increased progression-free survival by 3.2 months compared to docetaxel alone in KRAS-mutation positive NSCLC.

Mitogen-activated protein kinase, or MEK, is part of the MAPK pathway, which is frequently activated in cancer and is elevated in many different solid tumour types, including those featuring the KRAS mutation.

The KRAS mutation is present in 20 to 30 per cent of NSCLC tumours and AZ has partnered with Roche Molecular Systems to develop a KRAS diagnostic device to identify patients most likely to benefit from selumetinib.

The drug is also being studied across a range of other MEK-dependent cancers. AZ started a phase II study of selumetinib in thyroid cancer in August and will later this year begin a phase II study in patients with the rare cancer metastatic uveal melanoma.

Article by
Dominic Tyer

22nd October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics